An Investigational New Drug (IND) candidate developed by Xentria to suppress the physiologic response to tumor necrosis factor.
Sarcoidosis - A rare inflammatory disease that interferes with an organ’s structure and function.
Sarcoidosis is characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organ of the body.
Our ability to fight sarcoidosis is still lacking in many ways, making it an especially difficult disease for patients and physicians alike. Many people are left feeling frustrated and alone as they struggle to find answers and keep it from taking over their lives during their most productive years.
Since sarcoidosis is rare and symptoms vary widely, people can go for years without knowing they have it.1
There are no definitive tests or biomarkers, so it may take many doctor’s visits to rule out other options before receiving a diagnosis.
There are no approved medicines specifically for sarcoidosis.9 Steroids are the main treatment option, but they don’t work well for everyone and can cause or worsen other health problems like depression, weight gain, heart disease, and diabetes. 10,11,12
Most doctors have almost no training on sarcoidosis and lack the tools to manage treatment effectively over time. The measures that do exist don’t capture what’s most meaningful for patients, like fatigue or ability to work.
While the exact causes of sarcoidosis are unknown, research suggests that inflammatory pathways are likely a driving force. We are working to better understand these pathways and find promising targets for future medicines, which could redefine the standard of care and help us take back control from this devastating disease.
A trial designed to test the safety and initial clinical activity of XTMAB-16 in participants who have pulmonary involvement with or without extrapulmonary manifestations.